GLP-1 Blindness? What Is Known and What Is Not Known Yet
Please note
We don't know everything about GLP-1 medicines and the optic nerve yet. These facts can change as new studies come out. Please sign up for our newsletter to stay updated, and we'll keep this article updated.
Last updated: Nov 18, 2026
The short answer: What headlines call "GLP-1 blindness" is a rare eye problem called NAION. GLP-1 medicines for diabetes and weight loss, like Ozempic, Wegovy, Mounjaro and Zepbound, have been linked to a small risk of a sudden eye problem called NAION. NAION happens when blood flow to the front of the optic nerve drops, and it can leave lasting vision loss in one eye. It is rare. Regulators now put it at about 1 extra case per 10,000 people a year on semaglutide. An eye exam can show whether your optic nerve is crowded, which is one known risk factor. It cannot predict who will get NAION.
Here is what is known, what is not known yet, and what to do about it. For a quick summary and our optional $59 screening, visit our GLP-1 eye screening page.
NAION in plain words
Non-arteritic anterior ischemic optic neuropathy, or NAION, happens when the front of the optic nerve briefly does not get enough blood. The nerve swells and some of its fibers die. The result is painless vision loss in one eye. People often notice it first thing in the morning. It is not caused by inflamed arteries (that is the "arteritic" kind, which is treated differently).
Small cup, crowded nerve
Your optic nerve looks like a round disc in the back of the eye. In most eyes, the center has a pale hollow called the cup, usually 20% to 40% of the width of the disc. Picture a ring donut: the hole leaves space for about a million nerve fibers to pass through.
Some people are simply born with a small disc and almost no cup, more like a filled donut. Eye doctors call this a crowded disc, or a disc at risk. Because the fibers are packed so tight, a little swelling can pinch them. This crowded shape is the best-known built-in risk factor for NAION.

Illustration, not a patient photo. A normal cup (20% to 40%) next to a nerve with no cup (crowded).
A crowded disc does not rule out a GLP-1 medicine. It is a risk factor, and there is not yet enough research to say exactly how much it adds for someone on these drugs. Knowing about it helps you, your eye doctor and your prescriber decide together.
Even with a crowded optic nerve, this is not a reason to stop your GLP-1 medication. Never stop or change a medicine without talking to the doctor who prescribed it.
Three real optic nerves, side by side
These are images from three different eyes. Each eye has a fundus photo (a picture of the back of the eye) next to an optical coherence tomography (OCT) scan of the optic nerve head. The normal cup is about 20% to 40% of the disc. The images show how cup size can look. They do not diagnose anything, and they are not a promise about anyone's risk. All images are de-identified.
Eye 1: crowded optic disc (small or no cup, a "disc at risk")

Eye 2: cup about 30% of the disc

Eye 3: cup about 50% of the disc

What is known
- The first report came from a high-risk group. A 2024 study from Mass Eye and Ear in JAMA Ophthalmology found NAION in 8.9% of people with type 2 diabetes prescribed semaglutide over 3 years, compared with 1.8% on other diabetes drugs. But every patient came from a neuro-ophthalmology (nerve and vision) clinic, so they were already more likely to have optic nerve problems. Even the patients not on a GLP-1 had NAION far more often than the general public.
- Big national studies found a much smaller risk. In Denmark and Norway, about 2 to 3 out of 10,000 semaglutide users with diabetes had NAION each year, compared with about 1 out of 10,000 on an SGLT-2 drug. Another study of all 424,152 Danish people with type 2 diabetes found roughly double the risk.
- Regulators have acted. In June 2025, Europe's medicines agency called NAION a very rare side effect of semaglutide (up to 1 in 10,000 people). In November 2026 the FDA required a NAION warning on all GLP-1 labels. Across 126 clinical trials, the FDA counted 6.4 cases per 100,000 people a year on a GLP-1, compared with 3.8 on other treatments.
- Other risk factors matter too: diabetes, high blood pressure, sleep apnea, low blood pressure at night, smoking, high cholesterol, anemia, kidney disease, optic disc drusen and a past NAION in the other eye.
- Dialysis: in Dr. Reimbold's clinical experience, blood pressure can drop very low during or after dialysis, which can reduce blood flow to the optic nerve.
More facts worth knowing
- It usually affects one eye. But the other eye can be affected later. In a large NAION study, about 15% of people had it in the second eye within about 5 years (Newman et al., 2002). People with diabetes had a higher second-eye rate.
- There is no proven treatment. Getting seen the same day still matters, so your eye doctor can rule out other causes that need different care.
- Timing is not settled. In the first study, cases rose fastest in the first year on the medicine. In the all-Denmark study, the middle point was about 22 months after the first prescription.
- Tirzepatide (Mounjaro, Zepbound). A U.S. study of people with type 2 diabetes grouped semaglutide and tirzepatide together and found NAION in 0.04% over 2 years, compared with 0.02% on other diabetes drugs (Wang et al., 2025). A 2025 review of U.S. and World Health Organization side-effect report databases found no clear link between tirzepatide and this optic nerve problem. Its only clear signal for tirzepatide was diabetic eye disease, in the U.S. reports (Lakhani et al., American Journal of Ophthalmology, 2025). These are early data.
- Formulation may matter, but this is not proven. In a separate 2026 review of FDA side-effect reports, Wegovy (higher-dose semaglutide) had a stronger signal than Ozempic (Lakhani et al., British Journal of Ophthalmology, 2026). Reports like these can't prove cause.
- Diabetic retinopathy can worsen at first. In a 2-year trial, diabetic eye complications happened in 3.0% of people on Ozempic compared with 1.8% on placebo. The gap was bigger in people who already had diabetic retinopathy (8.2% compared with 5.2%). The Ozempic label says a fast improvement in blood sugar has been linked to a temporary worsening of diabetic retinopathy. If you have diabetic eye disease, keep your eye exams on schedule.
The big NAION study
Doctors have one large U.S. study that followed people with NAION. It is called the Ischemic Optic Neuropathy Decompression Trial, or IONDT. It tested whether a surgery on the optic nerve could help.
- When it ran. People joined from October 1992 to October 1994, at 25 eye centers across the U.S.[1] Doctors kept checking many of them for years. For the other-eye results below, the middle follow-up time was about 5 years.[2]
- How many people. 258 people were put into two groups by chance: surgery, or careful follow-up with regular eye checks and no surgery. In all, 418 people were followed.[2]
- Why it stopped early. The researchers stopped signing people up early. The early results showed the surgery did not help and may have caused harm.[3]
- What it found. Surgery did not help. In the early report, among people who had no surgery, about 4 in 10 eyes (42.7%) got somewhat better by 6 months, meaning they gained 3 or more lines on the eye chart. About 1 in 8 (12.4%) got worse, losing 3 or more lines.[3] By 2 years, about 3 in 10 (31.0%) were better and about 2 in 10 (21.8%) were worse than at the start.[4]
- The other eye. Over about 5 years, about 15 in 100 people (14.7%) got NAION in the other eye. It was more common in people with diabetes.[2]
This study was done long before GLP-1 medicines. It shows how NAION behaves in general. It does not tell us what GLP-1 medicines do.
Viagra-type medicines and a crowded optic nerve
Viagra-type medicines have also been linked to NAION. Experts think people with a crowded optic nerve ("disc at risk") may be at higher risk if they take them.[5] [6] The link is not proven, and for most people the added risk looks small.
- What they are. Viagra-type medicines are called PDE5 inhibitors: sildenafil (Viagra, Revatio), tadalafil (Cialis), vardenafil (Levitra) and avanafil (Stendra). Doctors prescribe them for erectile problems. Sildenafil (Revatio) is also used for high blood pressure in the lungs, in both men and women.[7]
- The FDA labels already warn about it. The labels say NAION has been reported rarely in people taking these medicines, and that it can cause permanent loss of vision. They also say people with a crowded optic nerve are considered at greater risk, and that there is not enough evidence to support screening people before they start the medicine.[5]
- What the studies found. Two studies compared the days right after taking the medicine with other days. They found about twice the risk of NAION: 2.15 times in one[8] and 2.27 times in the other (a borderline result).[9] One estimate is that weekly use adds about 3 cases per 100,000 men aged 50 and older each year.[8] A large insurance-records study found about twice the risk of ischemic optic neuropathy in regular users.[10]
- Not every study agrees. Several other large studies found no clear link.[11] [12] [13] So the link is possible but not proven. It is hard to separate these medicines from heart disease, diabetes and high blood pressure, which also raise the risk of NAION.[5]
- Crowded optic nerve. In one report of 5 patients who developed NAION after sildenafil, every one had a small cup in the other eye.[6] We did not find a study that measured how much extra risk these medicines add when the nerve is crowded.
- Women. The risk studies we found looked only at men.[12] A published case report describes NAION in a woman taking sildenafil for high blood pressure in the lungs.[14]
- How much vision is lost? It varies, and we did not find any study that reports what share of Viagra-type-linked NAION ends in blindness. Studies of NAION in general show a wide range. In a trial group that had careful follow-up only, 43% gained 3 or more lines on the eye chart by 6 months and 12% lost 3 or more lines.[3] By 24 months, 31% had gained and 22% had lost 3 or more lines.[4] In another study of untreated patients, 23% of eyes seen within 2 weeks of onset already had very poor vision (20/200 or worse) at the first visit.[15]
Dr. Reimbold's experience. Dr. Reimbold has seen this in her own practice: one patient developed NAION, and a neuro-ophthalmologist confirmed the NAION and agreed it was from the medicine. One patient is not proof, but it is why she talks with both women and men who have a crowded optic nerve about this risk if they take this type of medicine.
Never stop or change any medicine without talking to the doctor who prescribed it, and tell every doctor about all the medicines you take. If you ever have sudden vision loss in one eye, get medical care right away. The FDA labels say to stop the medicine and seek care if that happens.[5]
What is not known yet
- Cause or coincidence. These studies show a link, not proof. Many people who take GLP-1s already have diabetes, sleep apnea or high blood pressure, which raise NAION risk on their own.
- Why results differ. A study of more than 37 million adults with diabetes in 14 health databases found a modest increase in NAION risk with semaglutide, smaller than first reported, and a large TriNetX study found none at all. The FDA's own study of health-plan records saw a higher risk compared with DPP-4 drugs but not compared with SGLT-2 drugs.
- Tirzepatide and newer drugs. Most research is on semaglutide. Less is known about Mounjaro, Zepbound and newer pills.
- The crowded-nerve question. No study has yet measured how much a small cup adds for someone on a GLP-1.
Warning signs: don't wait
If you take a GLP-1 and notice any of these, call an eye doctor the same day:
- Sudden, painless dimming or loss of vision in one eye, often on waking
- A missing or dark area, often the upper or lower half of what you see
- Colors that look faded in one eye
- A hazy spot in the center of your vision
Check one eye at a time. Read more about symptoms that need a same-day visit.
Get your optic nerve checked at Bolt Eye Group
At a complete eye exam, our doctors look at the size and shape of your optic nerve and its cup, scan it with imaging, and can use ultrasound of the optic nerve to look for buried drusen and other signs of crowding. If you have diabetes, we also check for diabetic eye disease, which can flare when blood sugar falls quickly. See the tools we use on our technology in eye care page, and learn about vision and the brain.
If your nerve looks crowded, we will explain it in plain terms and can share the results with the doctor who prescribes your medicine. Please don't stop or change a medicine without talking to that doctor first. If you are ever diagnosed with NAION, call the doctor who prescribes your GLP-1 right away to talk about whether to keep taking it. Never stop or change a medicine without talking to that doctor.
New and optional: $59 GLP-1 optic nerve screening
On Ozempic, Wegovy, Mounjaro, Zepbound or another GLP-1? Add a GLP-1 optic nerve OCT screening to your complete eye exam. This screening is completely optional. It does not tell you whether you should stop or keep taking your medicine. It measures one risk factor (your optic nerve's cup size) so you and your doctors can make an informed choice. It costs $59, charged in addition to your regular eye exam fees, and it is separate from the retinal photos ($39 to $49) that are required with every comprehensive exam. Your doctor can help you decide if it is right for you. The scan maps your optic nerve, shows if it is crowded, and sets a baseline we can check against next time. The OCT scan is painless and not invasive. You simply look at a very dim light for a few seconds, and nothing touches your eye.
Book online: Canton, East Cobb, Lawrenceville, Riverdale or Johnson City. Mention the GLP-1 screening when you book or check in. See our GLP-1 eye screening page for details.
Frequently asked questions
How much does a GLP-1 eye screening cost?
The GLP-1 optic nerve OCT screening costs $59 at any Bolt Eye Group office. That is charged in addition to your regular eye exam fees, and it is separate from the retinal photos ($39 to $49) that are required with every comprehensive exam. Ask for it when you book or when you check in.
Is the GLP-1 screening required?
No. It is completely optional. The screening does not tell you whether you should stop or keep taking your medicine. It measures one risk factor (your optic nerve's cup size) so you and your doctors can make an informed choice. It is $59, on top of your regular exam fees, and separate from the retinal photos ($39 to $49) that are required with every comprehensive exam. Your doctor can help you decide if it is right for you.
Can GLP-1 medicines cause blindness?
NAION, the eye problem linked to GLP-1 medicines, is rare and usually affects part of the vision in one eye. It does not usually cause total blindness. GLP-1 medicines have been linked to a higher chance of NAION, a rare condition that damages the optic nerve and can cause lasting vision loss in part of one eye. Europe rates it a very rare side effect of semaglutide, up to 1 in 10,000 people, and the FDA now requires a NAION warning on every GLP-1 label.
Does Ozempic cause vision loss?
Ozempic (semaglutide) has been linked with NAION in several large studies, though not all of them. The added risk is small, roughly 1 extra case for every 10,000 people taking it for a year. Blurry vision in the first weeks is more often from changing blood sugar and usually settles.
Does tirzepatide (Mounjaro or Zepbound) cause NAION?
We do not know for sure. Most studies have looked at semaglutide. The FDA said in November 2026 that NAION has been reported with every GLP-1 medicine on the market, including tirzepatide, and it now requires a NAION warning on all of their labels.
What does vision look like with NAION?
Most people notice one eye is suddenly dim or blurry, often after waking. Part of the view may be missing, often the top or the bottom half, and colors can look washed out. It does not hurt.
Is NAION reversible?
There is no proven treatment, and the World Health Organization notes the vision loss is generally permanent. Some people get part of their vision back on their own over the next few months. Getting seen quickly still matters, so your eye doctor can rule out other causes.
Should I stop my GLP-1 if I have a small optic nerve cup?
Not on your own. A small cup is a risk factor, not a rule. Your eye doctor and the doctor who prescribed your medicine can weigh the benefits for your heart, blood sugar and weight against your eye risk together.
Book at a Bolt Eye Group office
On a GLP-1 or about to start one? Book a complete eye exam with an optic nerve check. Book online: Canton, East Cobb, Lawrenceville, Riverdale or Johnson City, or find your office.
Stay posted
Add your email and we'll send an update every few months (quarterly) on any new GLP-1 eye facts.
Email only. Unsubscribe any time.
Sources
- Hathaway et al. Risk of NAION in patients prescribed semaglutide. JAMA Ophthalmology, 2024.
- Simonsen et al. Use of semaglutide and risk of NAION: a Danish–Norwegian cohort study. Diabetes, Obesity and Metabolism, 2025.
- Grauslund et al. Once-weekly semaglutide and NAION in 424,152 Danish people with type 2 diabetes. International Journal of Retina and Vitreous, 2024.
- Cai et al. Semaglutide and NAION (37 million adults, 14 databases). JAMA Ophthalmology, 2025.
- Chou et al. Association between semaglutide and NAION (TriNetX). Ophthalmology, 2025.
- European Medicines Agency. PRAC concludes NAION is a very rare side effect of semaglutide. June 6, 2025.
- U.S. Food and Drug Administration. FDA requires safety labeling changes for GLP-1 RAs (NAION). November 9, 2026.
- World Health Organization. Semaglutide medicines and risk of NAION. June 27, 2025.
- Newman NJ, et al. The fellow eye in NAION (IONDT follow-up study). American Journal of Ophthalmology, 2002.
- Wang et al. Semaglutide or tirzepatide and optic nerve disorders in type 2 diabetes. JAMA Network Open, 2025.
- Lakhani et al. Association of GLP-1 receptor agonists with optic nerve and retinal adverse events. American Journal of Ophthalmology, 2025.
- Lakhani et al. Ischemic optic neuropathy with semaglutide: global observational analysis. British Journal of Ophthalmology, 2026.
- Ozempic U.S. prescribing information, section 5.3, diabetic retinopathy complications.
- StatPearls. Nonarteritic anterior ischemic optic neuropathy. NCBI Bookshelf.
Notes for the big NAION study and Viagra-type medicines sections
- Ischemic Optic Neuropathy Decompression Trial Research Group. The Ischemic Optic Neuropathy Decompression Trial (IONDT): design and methods. Control Clin Trials. 1998;19(3):276-296. doi:10.1016/s0197-2456(98)00003-8. https://pubmed.ncbi.nlm.nih.gov/9620811/ ↩
- Newman NJ, Scherer R, Langenberg P, et al. The fellow eye in NAION: report from the Ischemic Optic Neuropathy Decompression Trial follow-up study. Am J Ophthalmol. 2002;134(3):317-328. doi:10.1016/s0002-9394(02)01639-2. https://pubmed.ncbi.nlm.nih.gov/12208242/ ↩ ↩ ↩
- Ischemic Optic Neuropathy Decompression Trial Research Group. Optic nerve decompression surgery for nonarteritic anterior ischemic optic neuropathy (NAION) is not effective and may be harmful. JAMA. 1995;273(8):625-632. doi:10.1001/jama.1995.03520320035038. https://pubmed.ncbi.nlm.nih.gov/7844872/ ↩ ↩ ↩
- Ischemic Optic Neuropathy Decompression Trial Research Group. Ischemic Optic Neuropathy Decompression Trial: twenty-four-month update. Arch Ophthalmol. 2000;118(6):793-798. https://pubmed.ncbi.nlm.nih.gov/10865316/ ↩ ↩
- U.S. Food and Drug Administration. VIAGRA (sildenafil citrate) tablets, Prescribing Information, sections 5.3 and 6.2; and CIALIS (tadalafil) tablets, Prescribing Information, section 5.4. DailyMed, accessed November 18, 2026. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0b0be196-0c62-461c-94f4-9a35339b4501 Cialis label: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bcd8f8ab-81a2-4891-83db-24a0b0e25895 ↩ ↩ ↩ ↩
- Pomeranz HD, Smith KH, Hart WM, Egan RA. Sildenafil-associated nonarteritic anterior ischemic optic neuropathy. Ophthalmology. 2002;109(3):584-587. doi:10.1016/s0161-6420(01)00976-9. https://pubmed.ncbi.nlm.nih.gov/11874765/ ↩ ↩
- U.S. Food and Drug Administration. REVATIO (sildenafil citrate), Prescribing Information, section 5.4 Visual Loss. DailyMed, accessed November 18, 2026. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3bb9363e-b28d-4019-8aae-539233dca214 ↩
- Campbell UB, Walker AM, Gaffney M, et al. Acute nonarteritic anterior ischemic optic neuropathy and exposure to phosphodiesterase type 5 inhibitors. J Sex Med. 2015;12(1):139-151. doi:10.1111/jsm.12726. https://pubmed.ncbi.nlm.nih.gov/25358826/ ↩ ↩
- Flahavan EM, Li H, Gupte-Singh K, et al. Prospective case-crossover study investigating the possible association between nonarteritic anterior ischemic optic neuropathy and phosphodiesterase type 5 inhibitor exposure. Urology. 2017;105:76-84. doi:10.1016/j.urology.2017.02.044. https://pubmed.ncbi.nlm.nih.gov/28336289/ ↩
- Etminan M, Sodhi M, Mikelberg FS, Maberley D. Risk of ocular adverse events associated with use of phosphodiesterase 5 inhibitors in men in the US. JAMA Ophthalmol. 2022;140(5):480-484. doi:10.1001/jamaophthalmol.2022.0663. https://pubmed.ncbi.nlm.nih.gov/35389459/ ↩
- Nathoo NA, Etminan M, Mikelberg FS. Association between phosphodiesterase-5 inhibitors and nonarteritic anterior ischemic optic neuropathy. J Neuroophthalmol. 2015;35(1):12-15. doi:10.1097/WNO.0000000000000186. https://pubmed.ncbi.nlm.nih.gov/25295683/ ↩
- Penedones A, Alves C, Batel Marques F. Risk of nonarteritic ischaemic optic neuropathy with phosphodiesterase type 5 inhibitors: a systematic review and meta-analysis. Acta Ophthalmol. 2020;98(1):22-31. doi:10.1111/aos.14253. https://pubmed.ncbi.nlm.nih.gov/31559705/ ↩ ↩
- Belladelli F, Li S, Zhang CA, et al. Use of phosphodiesterase 5 inhibitors is not associated with ocular adverse events. J Sex Med. 2023;20(12):1399-1406. doi:10.1093/jsxmed/qdad137. https://pubmed.ncbi.nlm.nih.gov/37861186/ ↩
- Prat NM, Sánchez-Dalmau BF, Foroozan R. Not just for men. Surv Ophthalmol. 2011;56(2):173-177. doi:10.1016/j.survophthal.2010.06.001. https://pubmed.ncbi.nlm.nih.gov/21035828/ ↩
- Hayreh SS, Zimmerman MB. Nonarteritic anterior ischemic optic neuropathy: natural history of visual outcome. Ophthalmology. 2008;115(2):298-305.e2. doi:10.1016/j.ophtha.2007.05.027. https://pubmed.ncbi.nlm.nih.gov/17698200/ ↩
This article is for general education and is not a diagnosis or medical advice. The illustration is not a patient photo. Do not stop or change any medicine without talking to the doctor who prescribed it. If you have sudden vision loss, call an eye doctor right away or go to an emergency room.
Your next step: book an exam at the Bolt Eye Group office near you.